{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:55:23Z","timestamp":1761519323478,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.eprac.2021.01.017","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T21:23:20Z","timestamp":1612992200000},"page":"886-893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1\/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes"],"prefix":"10.1016","volume":"27","author":[{"given":"David Tak Wai","family":"Lui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikki","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol Ho Yi","family":"Fong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan Chun Hong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne Wing Yan","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland Ching Yu","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerry Gin Wai","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan Cho Wing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tan To","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu Cho","family":"Woo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen Siu Ling","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Yau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.eprac.2021.01.017_bib1","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1089\/thy.2020.0032","article-title":"Thyroid toxicity following immune checkpoint inhibitor treatment in advanced cancer","volume":"30","author":"Muir","year":"2020","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.eprac.2021.01.017_bib2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.eprac.2021.01.017_bib3","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12957-020-01933-5","article-title":"The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis","volume":"18","author":"Chen","year":"2020","journal-title":"World J Surg Oncol"},{"issue":"3","key":"10.1016\/j.eprac.2021.01.017_bib4","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of Indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.eprac.2021.01.017_bib7","first-page":"2033","article-title":"Endocrinopathies associated with immune checkpoint inhibitor cancer treatment: a review","volume":"9","author":"Okura","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"1","key":"10.1016\/j.eprac.2021.01.017_bib8","doi-asserted-by":"crossref","first-page":"101370","DOI":"10.1016\/j.beem.2019.101370","article-title":"New insight in endocrine-related adverse events associated to immune checkpoint blockade","volume":"34","author":"Elia","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2021.01.017_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216954","article-title":"Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab","volume":"14","author":"Yamauchi","year":"2019","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.eprac.2021.01.017_bib10","doi-asserted-by":"crossref","first-page":"824","DOI":"10.4158\/EP-2018-0472","article-title":"Baseline TSH level is associated with risk of anti-PD-1-induced thyroid dysfunction","volume":"25","author":"Pollack","year":"2019","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.eprac.2021.01.017_bib11","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1503\/cmaj.180870","article-title":"Adverse events associated with immune checkpoint inhibitor treatment for cancer","volume":"191","author":"Esfahani","year":"2019","journal-title":"CMAJ"},{"issue":"15_suppl","key":"10.1016\/j.eprac.2021.01.017_bib12","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1200\/JCO.2018.36.15_suppl.3064","article-title":"Correlation between immune-related adverse events (irAEs) and efficacy in patients with solid tumors treated with immune-checkpoints inhibitors (ICIs)","volume":"36","author":"Riudavets","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.eprac.2021.01.017_bib13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s40425-019-0779-6","article-title":"Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis","volume":"7","author":"Xing","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"3","key":"10.1016\/j.eprac.2021.01.017_bib14","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.eprac.2021.01.017_bib15","first-page":"1","article-title":"Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer","volume":"7","author":"Kim","year":"2017","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.eprac.2021.01.017_bib16","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.eprac.2021.01.017_bib17","doi-asserted-by":"crossref","first-page":"e893","DOI":"10.1016\/j.cllc.2018.08.008","article-title":"Incidence, risk factors, and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer","volume":"19","author":"Owen","year":"2018","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"10.1016\/j.eprac.2021.01.017_bib18","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00432-018-2805-3","article-title":"Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis","volume":"145","author":"Ricciuti","year":"2019","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"2","key":"10.1016\/j.eprac.2021.01.017_bib19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"issue":"10","key":"10.1016\/j.eprac.2021.01.017_bib20","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1007\/s00198-020-05395-z","article-title":"HbA1c variability, in addition to mean HbA1c, predicts incident hip fractures in Chinese people with type 2 diabetes","volume":"31","author":"Lui","year":"2020","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.eprac.2021.01.017_bib21","article-title":"Different glycaemia-related risk factors for incident Alzheimer\u2019s disease in men and women with type 2 diabetes-A sex-specific analysis of the Hong Kong diabetes database [published online ahead of print, 2020 Sep 1]","author":"Lee","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"issue":"5","key":"10.1016\/j.eprac.2021.01.017_bib22","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/jdi.13368","article-title":"A\u00a0territory-wide study on the impact of COVID-19 on diabetes-related acute care","volume":"11","author":"Lui","year":"2020","journal-title":"J\u00a0Diabetes Investig"},{"key":"10.1016\/j.eprac.2021.01.017_bib23","first-page":"dgaa813","article-title":"Thyroid dysfunction in relation to immune profile, disease status and outcome in 191 patients with COVID-19 [published online ahead of print, 2020 Nov 3]","author":"Lui","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2021.01.017_bib24","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/cen.14135","article-title":"Thyroid disorders in programmed death 1 inhibitor-treated patients: is previous therapy with tyrosine kinase inhibitors a predisposing factor?","volume":"92","author":"Sbardella","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"10.1016\/j.eprac.2021.01.017_bib25","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","article-title":"Analysis of survival by tumor response","volume":"1","author":"Anderson","year":"1983","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.eprac.2021.01.017_bib26","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","author":"Delivanis","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2021.01.017_bib27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A\u00a0systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"De Filette","year":"2019","journal-title":"Horm Metab Res"},{"issue":"10","key":"10.1016\/j.eprac.2021.01.017_bib28","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1089\/thy.2018.0116","article-title":"Immune-related thyroiditis with immune checkpoint inhibitors","volume":"28","author":"Iyer","year":"2018","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.eprac.2021.01.017_bib29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2018","journal-title":"Endocr Rev"},{"issue":"3","key":"10.1016\/j.eprac.2021.01.017_bib30","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jhep.2019.05.014","article-title":"Nivolumab in advanced hepatocellular carcinoma: sorafenib-experienced Asian cohort analysis","volume":"71","author":"Yau","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"10088","key":"10.1016\/j.eprac.2021.01.017_bib31","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.eprac.2021.01.017_bib32","article-title":"Autoimmune endocrinopathies: an emerging complication of immune checkpoint inhibitors [published online ahead of print, 2020 Sep 4]","author":"Quandt","year":"2020","journal-title":"Annu Rev Med"},{"issue":"3","key":"10.1016\/j.eprac.2021.01.017_bib33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1210\/js.2017-00432","article-title":"Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study","volume":"2","author":"Kobayashi","year":"2018","journal-title":"J\u00a0Endocr Soc"},{"issue":"1","key":"10.1016\/j.eprac.2021.01.017_bib34","first-page":"32","article-title":"Anticancer drug-induced thyroid dysfunction","volume":"16","author":"Bhattacharya","year":"2020","journal-title":"Eur Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2021.01.017_bib35","first-page":"1","article-title":"Immune-related adverse events and antitumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"30","key":"10.1016\/j.eprac.2021.01.017_bib36","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1200\/JCO.19.00318","article-title":"Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody","volume":"37","author":"Ellen Maher","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"22 Pt 1","key":"10.1016\/j.eprac.2021.01.017_bib37","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade","volume":"13","author":"Downey","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.eprac.2021.01.017_bib38","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2019.0046","article-title":"Association of anti-programmed cell death 1 cutaneous toxic effects with outcomes in patients with advanced melanoma","volume":"5","author":"Quach","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eprac.2021.01.017_bib39","doi-asserted-by":"crossref","unstructured":"Cortellini A, Friedlaender A, Banna GL, et\u00a0al. Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression \u2265 50% and their relationship with clinical outcomes. Clin Lung Cancer. Published online June 2020. doi:10.1016\/j.cllc.2020.06.010","DOI":"10.1016\/j.cllc.2020.06.010"},{"key":"10.1016\/j.eprac.2021.01.017_bib40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X21000306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X21000306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:10:21Z","timestamp":1761516621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X21000306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1530891X21000306"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2021.01.017","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1\/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2021.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}